A Stress Testing Benchmarking Study
|
|
- Nora Tucker
- 6 years ago
- Views:
Transcription
1 A Stress Testing Benchmarking Study Karen M. Alsante, Linda Martin, and Steven W. Baertschi* Stress testing is becoming increasingly important in testing new small-molecule drug candidates. To better understand current stress-testing practices in the pharmaceutical industry, the authors conducted a benchmarking survey to which 2 pharmaceutical companies responded. The study addressed a range of issues such as stress testing study design, types of conditions, procedures, and the company organization used to conduct stress testing. This article reviews the key findings from the survey. IMAGE 1 Karen M. Alsante, PhD, is a senior research investigator in the analytical research and development department at Pfizer Global Research & Development, Groton, Connecticut. Linda Martin is a principal consultant at KMR Group, Chicago, Illinois. Steven W. Baertschi, PhD, is a senior research scientist at Eli Lilly and Company, Indianapolis, Indiana, tel , fax *To whom all correspondence should be addressed. Stress testing (or forced degradation studies) is an important part of the drug development process, and the pharmaceutical industry s considerable interest in this topic has led to the publication of an article by the Pharmaceutical Research and Manufacturer s of America (PhRMA) in Pharmaceutical Technology (1). Although the concept of stress testing is not new to the pharmaceutical industry, the procedure was not clearly defined until the International Conference on Harmonization () provided a definition in its guidance on stability. The guideline indicates that stress testing is designed to help determine the intrinsic stability of the molecule by establishing degradation pathways in order to identify the likely degradation products and to validate the stabilityindicating power of the analytical procedures used (2). Because the definition leaves the details of the investigations to the pharmaceutical researcher, the practices that companies use to conduct stress testing studies can vary tremendously and therefore have a significant effect on the quality of the analytical methodology used throughout the industry. The intent of this study about stress testing is to survey stress testing practices in the industry and to provide a thorough comparative analysis of approaches to stress testing. The authors hope that these survey results will provide further guidance about stress testing to the industry. Stress testing is a critical component of drug development. By generating key stress-testing samples (i.e., partially degraded samples stressed under various conditions), predictive degradation information can be obtained early in the process and can be of significant value to a drug company in terms of time and money. In addition, stress testing can help in the selection of more-stable drug substance salt forms and drug formulations. Stress testing also is becoming increasingly important in testing new molecules. Methods developed by stress testing and the stability information gained from those methods can have a significant effect on the actual compound selected for development. Therefore, to understand the current state of stress testing in the pharmaceutical industry, a benchmarking survey focusing on the methods and practices was conducted in November 21. The survey was sponsored by Eli Lilly and Company (Indianapolis, IN) and Pfizer Inc. (Groton, CT). KMR Group, Inc. (KMR, Chicago, IL), a management consulting firm that specializes in benchmarking, conducted the study. 6 Pharmaceutical Technology FEBRUARY 2
2 The study addressed a range of issues, including stress testing design (i.e., how companies design stress testing studies and the approaches used) stress testing activity (i.e., types of stress testing conducted such as oxidative and the procedures used) organization (i.e., how companies are structured to oversee their stress testing activities and resources). The survey focused on stress testing studies pertaining to small-molecule drugs (i.e., nonbiologicals or nonprotein) and did not include monoclonal antibodies. Information related to small peptides was only included if the drug was going to be registered with the Center for Drug Evaluation and Research. The study encompassed only stress testing studies, not formal stability studies such as accelerated and long-term stability studies. The survey attempted to compare general internal practices rather than the details of each exception to the general practice or outsourcing practices. Therefore, companies were asked to focus on the current predominant internal practice or method at their company. If important exceptions to the general rule existed, participants were asked to note them. Both pharmaceutical and contract laboratories were invited to participate. Twenty companies provided responses to the survey. Of these, eleven are large pharmaceutical companies, four are midsize pharmaceutical companies, and four are contract services companies. Key findings Stress testing as a function. More than two-thirds of the companies responded that no defined stress-testing group existed within their company. For the companies that have defined stress-testing groups, roughly two-thirds are centralized (i.e., report to a worldwide head). Regardless of whether a defined group exists, most stress testing resources report their findings within the analytical chemistry function. Stress testing as a discipline. Most companies have a standardized approach to the design of stress testing studies. Seventy percent of these companies follow a standard operating procedure (SOP), and % of study participants require a protocol (see Organization of stress testing section). Types of stress testing studies performed. All companies perform stress testing on the drug substance using a variety of methods, including acid base solution, oxidative, thermal humidity, and photostability. Each of these methods is used on the drug substance by at least 9% of companies. Fewer companies perform stress testing on the drug product (9%), and not all methods are used with the same frequency. For example, only 6% of companies perform acid base solution stress testing studies on the drug product and 6% perform oxidative studies, whereas thermal humidity and photostability studies are performed by 9% of companies. Timing of stress testing studies. The majority of companies perform studies on the drug substance and the drug product in the preclinical stage. The practice of repeating stress testing studies varies by stage of development. Studies are repeated on the drug substance between the preclinical and registration stages, and studies are repeated on the drug product between Phase I and registration as the final commercial formulation is developed. How stress testing studies are conducted. Seventy percent of companies generally identify the major degradation products formed during stress testing studies. Most companies attempt to induce at least 2% degradation of the drug substance before considering stress testing to be complete. The primary methods used to analyze stress testing studies are liquid chromatography (LC) diode array (6%) and LC UV (%). Survey methods The survey was conducted confidentially using a questionnaire to capture individual company responses. KMR worked closely with the sponsor companies (Eli Lilly and Pfizer) to ensure that the survey s goals would be met. A list of questions was developed by the sponsor companies as the basis for the survey. With the guidance and direction of the sponsor companies, KMR turned the list of questions into a formal, detailed survey. KMR was responsible for distributing the final questionnaire to each participating company, and survey responses were submitted directly to KMR. To ensure comparability with companies, each company s data were reviewed to ensure consistency with the definitions and queried if needed. All data submitted by each company remained confidential and were analyzed and presented in aggregate to maintain confidentiality. All participants received a final copy of the report. Organization of stress testing The stress testing function is structured quite differently among the companies surveyed. A third (six) of the companies organize stress testing into a defined group. Of those six companies, four are centralized. In most companies, the personnel responsible for stress testing report their findings within the analytical chemistry function. Of the six companies with a formal, defined stress-testing group, five report to the head of analytical chemistry, and one reports to the head of early development. All twenty companies were asked who is primarily responsible for designing and conducting stress testing studies in each phase (see Table I). Individual scientists was the most frequently cited primary resource responsible for both designing and conducting stress testing studies, regardless of the phase of development. However, 2% of companies have a specialized degradation group that performs stress testing studies during some phase of development, most often after preclinical development. Although none of the companies indicated that a robot system was the primary resource for either designing or conducting stress testing studies, one company selected it as a secondary resource or alternative for conducting stress testing studies in Phases II and III. The primary reasons for conducting stress testing studies vary significantly among companies (see Figure 1). Method development was selected with the highest frequency, although it was selected by only seven companies. Other common responses were method validation, selected by four companies, and stability support and distribution, selected by three companies. Regulatory compliance was the most popular secondary response for performing stress testing studies; however, the majority of companies selected all categories as secondary reasons. 62 Pharmaceutical Technology FEBRUARY 2
3 Method development Method validation Primary Secondary Stability support & distribution Preformulation & excipient compatibility Regulatory compliance Figure 1: Predominant reasons to perform stress testing studies (n 2) LC diode array One company commented that choosing a single primary reason is difficult because all the reasons that were listed are important (see Figure 1). Thirteen companies have a standardized approach to designing stress testing studies. Of the thirteen, 7% follow an Table I: Resources primarily responsible for conducting stress testing studies by phase. SOP. Eleven companies require a protocol to conduct stress testing studies, and 7% of those use a standardized approach. Most (eight out of nine) companies that follow SOPs also require a protocol for stress testing studies. All but one company typically generate a technical report for internal purposes. More than three quarters of respondents generate a technical report for 7% of the studies performed. One company commented that reports are generated for all new drug applications and for % of preclinical- or early-phase stress testing studies. Most companies provide some version of a technical report for submission purposes. Ten companies give a summary (one as an addendum to the chemistry, manufacturing, and controls section), and four companies did not know. Activity This section of the survey focused on methods used to analyze stress testing samples and the appropriate stage of development to perform stress testing studies. Methods used to analyze stress testing samples included either LC diode array or LC UV as the primary method of analysis. Eighteen companies cited LC mass spectrometry (MS) as a secondary method. One company stated that it uses LC MS, capillary electrophoresis, and thin-layer chromatography (TLC) for selected samples. Another company commented that it uses LC NMR only for specific identification projects. The typical methodologies used by respondents to analyze stressed samples are outlined in Figure 2. Most (twelve) companies first perform stress testing studies on the drug substance in the preclinical stage. Five companies first perform stress testing in the discovery stage, and the remaining two companies first perform stress testing in Phase I and II, respectively. Seventeen companies repeat stress testing studies, and eight companies repeat stress testing studies in more than one phase. Eighteen companies (out of twenty) perform some kind of stress testing studies on the drug product. These companies perform drug product studies between discovery and Phase II, but usually in the preclinical stage. Phases in which these studies are repeated vary from Phase I to registration. Similar to the practices for drug substance studies, eight companies repeat drug product studies in more than one phase. Fourteen companies generally identify major degradation products observed during stress testing on the drug substance even if the degradation products are not observed during stability studies (e.g., 2 C/6% RH, C/6% RH, 4 C/7% RH). Of the fourteen, ten companies identify all major degradation products that form Conduct Resource Discovery Preclinical Phase I Phase II Phase III Registration Specialized degradation group Robot system Contract laboratory Individual scientists Other 1 N/A Total Other Primary Secondary LC UV LC MS TLC LC NMR Figure 2: Methods used to analyze samples, and the top five responses (n 2). in stress testing, and two companies generally identify only those approaching thresholds (i.e., the degradation products that are formed during formal stability that approach thresholds). One company stated that the identification effort varies from drug to drug, 64 Pharmaceutical Technology FEBRUARY 2
4 RRT + LC MS RRT + isolation + structure RRT + UV (PDA) RRT RRT + LC NMR Elemental analysis Other Figure : degradant characterization methodologies (n 2, and RRT is relative retention time). Number of companies Figure 4: ph level covered In acid base studies. Drug substance (n 19). Number of companies Figure : ph level covered In acid base studies. Drug product (n 1). and another company identifies only those at or above threshold limits. Companies were then asked to indicate the typical degradation-characterization methodologies (i.e., for structure elucidation and peak tracking) that were implemented. are shown in Figure. Acid base testing Nineteen out of the twenty companies participating in the survey perform acid base stress testing on the drug substance. Approximately 6% of companies perform acid base testing on the drug product, and 1% perform acid base testing on intermediates. When the desired drug product is a solution dosage form, acid base stress testing studies are used more frequently than when the drug product is a solid oral dosage form. Figure 4 shows the various ph range combinations that companies use to perform acid base studies on the drug substance. Nineteen companies typically perform stress testing on the drug substance in solutions at different phs. Each color represents a range combination. Companies are classified with the combination that most accurately represents their response. For example, in Figure 4, three companies indicated using ph ranges of 1 2 and 12 1 (represented by the orange bars in Figure 4). Fortytwo percent of companies cover a wide range (1 1), 2% cover the outer ranges only, and roughly 2% cover phs in the low ( 2), mid ( 9), and high (12 1) ranges. Approximately 1% cover phs in the low to mid ranges. Figure shows various ph range combinations that companies use to perform acid base studies on drug product. Thirteen companies typically perform stress testing on drug products in solutions at different phs. Thirty percent of these companies cover a continuous range of phs from 1 1. Another % use low, mid, and high ph ranges (12 1). Roughly 2% cover the middle ranges only, and 1% cover the outer ranges only. For acid base stress testing, 14 companies stress at one concentration, and four companies use multiple concentrations. Three companies indicated that they use solubility-dependent concentrations, and one company indicated that it uses compound-dependent concentrations. Two companies stated that they may use one or multiple concentrations depending on the situation. Fifteen companies use a concentration between.1 and 1. mg/ml. Phosphate is the most common buffer used among the 11 companies that use buffers. Of these, phosphate is used by all companies to acidify solutions and used by 64% to basify solutions. One company stated that the method used to control ph depends on the drug substance. Eighteen companies use cosolvents to help solubilize the drug substance. Acetonitrile (ACN) and methanol are the most commonly used cosolvents for acid base stress testing. One company stated that it uses cosolvents only when necessary, which, in practice, meant routinely. The percent of studies involving the use of cosolvents varies among companies but is 7%. Most companies use low temperature ranges (ambient 7 C) for acid base studies on the drug substance. Only a few companies use temperatures 7 C. Conditions used are more extreme if the drug substance does not degrade easily in acid base studies. Companies tend to use a low (1 2) and high (12 1) ph range to promote degradation. Six companies use temperatures 9 C if the compound does not degrade easily; however, the majority of the companies do not exceed 8 C routinely. The maximum time companies will stress samples if no degradation occurs varies among companies. Twenty percent of companies will stress the samples for 2 days or more. Most companies attempt to induce 2% degradation of the drug substance to consider the stress test complete. 66 Pharmaceutical Technology FEBRUARY 2
5 Glossary AAPH: 2,2 -azobis(2-amidopropane)dihydrochloride. AIBN: 2,2 -azobisisobutyronitrile. AMVN: 2,2 -azobis(2,4-dimethylvaleronitrile). DPPH: 1,1-diphenyl-2-picrylhydrazyl. Acid base solution stress testing: forced degradation studies designed to test the stability of compounds primarily by exposure to acid base solutions in a variety of ph conditions. Ambient: the surrounding laboratory temperature of the environment in which the study is performed. Confirmatory photostability studies: studies designed to determine the degree of photodegradation protection required and to provide the information necessary for handling, packaging, and labeling (see Q1B glossary). Cosolvents: an inorganic or organic liquid used as a vehicle for the preparation of solutions or suspensions in the synthesis of a new drug substance or the manufacture of a new drug product. Degradation: the change of a compound into a different chemical structure induced over time by the action of elements such as light, temperature, ph, water, or by reacting with an excipient and/or the immediate container closure system. Drug product: the finished dosage form (e.g., tablet, capsule, etc.) that contains a drug substance generally, but not necessarily, in association with other active or inactive ingredients. Drug substance: the active ingredient intended to diagnose, treat, cure, or prevent disease or affect the structure or function of the body, excluding other inactive substances used in the drug product. Excipient: anything other than the drug substance in a dosage form. Forced degradation studies: see stress testing. stability studies: long-term and accelerated (and intermediate) studies undertaken on primary and/or commitment batches according to a prescribed stability protocol to establish or confirm the retest period of a drug substance or the shelf life of a drug product. Intermediate: compound produced during the synthesis of the drug substance that may undergo further synthetic modification to produce the drug substance. Neutralize: a process to prevent further reaction in acid base solution stress testing studies (e.g., by addition of an acid or base). Oxidative stress testing: forced degradation studies designed to test the susceptibility of compounds to oxidative degradation. Photostability Option 1: exposure of the sample to any light source that is designed to produce an output similar to the D6/ID6 emission standard such as an artificial daylight fluorescent lamp combining visible and UV outputs, xenon, or metal halide lamp. D6 is the internationally recognized standard for outdoor daylight, and ID6 is the equivalent indoor indirect daylight standard (see Q1B glossary}. Photostability Option 2: Exposure of the sample to a cool white fluorescent lamp designed to produce an output similar to that of ISO 1977 and to a near fluorescent lamp having a spectral distribution from 2 to 4 nm (see Q1B glossary). Photostability stress testing: Forced degradation studies (as opposed to confirmatory studies) designed to test the stability of compounds under light exposure (i.e., visible and UV light) (see Q1B glossary). Quench: a process to prevent further reaction in oxidative studies (e.g., by addition of an antioxidant). Thermal humidity stress testing: forced degradation studies designed to test the stability of compounds by exposing them to different thermal and humidity conditions. Sample: the drug substance or drug product being tested. Stress testing: studies undertaken to elucidate intrinsic stability attributes of the drug substance or drug product (see Q1A definition). Also referred to as forced degradation studies. Solid-state stress testing: studies that determine the solid-state stability of the drug substance or drug product. Oxidation Nineteen companies perform oxidative stress testing on the drug substance. Approximately 6% perform oxidative stress testing on the drug product, and 1% of companies perform oxidative stress testing on intermediates. A third of companies perform stress testing on the drug substance only. When performing oxidative stress testing, responses also show that Nineteen companies use peroxides as an oxidative measure. Five companies use a radical initiator. Three companies use pressured oxygen. Three companies use transition metals. Only two companies use bubbled oxygen. Figures 6 9 show types of oxidative stress tests and their typical performance conditions. The number of companies that perform each type is shown in the center of the diagrams. Each pie chart in the figures represents a specific condition and is divided according to the number of responses for that condition. For example, in the peroxide pie chart that shows typical temperatures, 84% of the companies selected ambient C, 11% selected 1 C, and only % selected C. Peroxides (n 19). All companies use hydrogen peroxide. The typical concentration selected by a majority of companies (6%) is 1 %. The typical temperature range selected by most companies (84%) is ambient C. The maximum study duration selected was the same for one and seven days (7% for both) (see Figure 6). Radical initiator (n ). The typical initiator used by four out of five companies is AIBN (see Glossary). The typical solvent used by four out of five companies is ACN water. The typical temperature used by three out of five companies is 1 4 C. The maximum study duration selected is 1 (one company), 7 (two companies), and 14 days (two companies) (see Figure 7). Transition metals (n ). All three companies use both copper (Cu II ) and iron (Fe III ) as the typical metals. Two companies use similar concentrations,. and 1. mm, respectively, and one company uses a significantly higher concentration (2 mm). The typical solvent used by all companies is aqueous water. The typical temperature used by two out of the three companies is 1 4 C. The maximum study duration varies among companies from 1 to more than 14 days (see Figure 8). Pressured oxygen (n ). The typical pressure is 1 or Pharmaceutical Technology FEBRUARY 2 67
6 peroxide Hydrogen peroxide 1 % <1% > 1% >1% concentration Figure 6: for peroxide. initiator ACVA ACN AIBN ACN water solvent 19 companies temperature > C 1 4 C companies 14 days >14 days Figure 7: for radical initiators. C 1 day 7 days study duration temperature C > C 1 4 C 7 14 days days 1 day study duration psi. One company stated that the pressure varies. The typical temperature is C for two companies and ambient C for one company. The maximum study duration varies among the three companies from 1 to more than 14 days (see Figure 9). Bubbled oxygen (n 2). The conditions for bubbled oxygen are almost identical for both companies. The typical temperature used by both companies is ambient C. The maximum study duration is 7 days for both companies. However, the flow rate is different; one uses 1 cc/min, and the other uses 1 cc/min (see Figure 9). Four companies typically quench oxidative studies. Of these four companies, three companies quench peroxide studies only and use reductants as the quenching method (e.g., sodium metabisulfite, sodium sulfite, and sodium thiosulfate). One company quenches only studies involving radical initiators and pressured oxygen using acid chelators as the quenching method. Thermal humidity studies All companies perform thermal humidity stress testing on the drug substance, 9% of companies perform stress testing on the drug product, and 2% perform stress testing on intermediates. Two companies perform stress testing only on the drug substance. Most companies perform thermal humidity stress testing studies in both open and closed containers; however, 2% of companies use only open containers, and two companies use only closed containers. Thirteen companies use a variety of temperature ranges when performing typical thermal humidity stress testing studies on the drug substance, whereas seven companies use only one range. Most companies (7%) typically test at a range of 1 7 C. If the drug substance does not degrade easily, % of companies stress solid-state samples at 9 C, and 2% of companies stress samples at 71 9 C (see Figure 1). When conducting thermal humidity stress testing studies on the drug product, 72% of companies use a temperature range of 41 or 1 7 C. If the drug product does not degrade easily, 44% of companies stress solid-state samples at a range 7 C. From these data, it can be concluded that the drug substance is stressed at higher temperature ranges than the drug product. More than % of companies stress solid-state samples of the drug substance in a variety of humidity ranges (see Figure 11). Eight companies use only one range. The typical range used by most companies is 1 7%. If the drug substance does not degrade easily, 9% of companies stress solid-state samples 1% humidity, and nine of these companies stress at 7% humidity. Only one company uses an ambient or uncontrolled humidity range. For the drug product, the typical humidity range used most often and selected by 88% of companies is 1 7%. If the drug product does not degrade easily, all companies use a humidity range of 1%. duration for performing thermal humidity studies on the drug substance varies among companies (see Figure 12). The duration selected most frequently (chosen by 4% of the companies) was 6 weeks; % selected a duration of longer than six weeks. If the drug substance does not degrade easily, % of companies use a duration longer than six weeks. For the drug product, % of companies use a range of longer than 6 weeks. If the drug product does not degrade easily, 67% of companies use a duration longer than six weeks. Photostability studies Eighteen out of nineteen companies perform photostability stress testing on the drug substance and the drug product. Roughly 16% of the companies perform photostability stress testing on intermediates. One company performs stress testing only on the drug substance, and another company performs stress testing only on the drug product. The majority of companies (6%) use the standard for their typical visible-light dose range (i.e., overall illumination is 1.2 million lux h) (2). Thirty-seven percent use a range greater than the standard. visible-light dose ranges vary among companies (see Figure 1). Eighty-nine percent use a maximum visible-light dose range greater than the standard; however, only two companies use a maximum visible-light dose range 1 times. Most companies (67%) use the standard for their typical UV-light dose range (i.e., overall integrated near-uv energy of 2 watt h/m 2 ) (see Figure 14) (2). UVlight dose ranges vary among companies; however, 67% of companies use a UV-light dose range that is 2 times the standard. Of these, two companies use a UV-light dose range 1 times. 68 Pharmaceutical Technology FEBRUARY 2
7 metals Cu II and Fe III concentration 1.. mm mm 2 mm companies temperature 1 4 C C C 1 7 C 71 9 C >9 C Aqueous water >14 days 7 days 1 day Figure 1: Temperature ranges used to stress samples. Drug substance (n 2). solvent study duration Figure 8: for transition metals. flow rate cc/min 1 cc/min uncontrolled >2% 2 % 1 7% >7% 2 companies Figure 11: Relative humidity ranges used to stress samples. Drug substance (n 19). C temperature C > C solvent 1 psi psi pressure companies 7 days study duration >14 7 days days 14 days study duration 9 6 <1 1 > 6 >6 12 >12 Weeks Figure 9: for bubbled oxygen (top) and pressured oxygen (bottom). Figure 12: Thermal/humidity duration used to stress samples. Drug substance (n 2). Fourteen companies perform photostability studies on the drug substance in solution. Of these, three companies perform solution photostability stress testing only if the drug will be marketed as a solution, cream, or syrup. Five companies do not perform photostability studies in solution. Four companies expose solutions to more than one ph if the drug substance has ionizable function groups. In an comparison of Option 1 and 2 (see Glossary) for photostability stress testing: Eighteen companies perform photostability studies using an photostability option (only one company does not use either option). Ten companies use photostability Option 1 for 7% of their studies 7 Pharmaceutical Technology FEBRUARY 2
8 > >1 Figure 1: and maximum visible-light dose ranges ( 1.2 million lux h) (n 19). Six companies use photostability Option 2 for 7% of their studies Two companies use both Option 1 and 2 for 1% of their studies. Sixteen companies perform both stress testing and confirmatory studies. Of these, 81% use the same photostability option for both stress testing and confirmatory studies. Three companies do not perform confirmatory studies. For Option 1 photostability stress testing: Most companies (86%) use the Atlas manufacturer light instrument. One company uses a home-built model. One company uses a Powers Scientific model. For Option 2, companies use more manufacturers: Three companies use Southern New England Lighting. Three companies use Environmental Specialties. One company uses Sanyo Gallenkamp. One company uses Percival Scientific. Two companies use home-built models. Most companies perform light measurements using radiometers or photometers. Twelve companies use an external model, and seven companies use a built-in model. Figure 14: and maximum visible-light dose ranges ( 2 watt h/m 2 ) (n 18). Conclusion Although stress testing has played a critical role in the drug development process, some have called it an artful science with a diversity of approaches depending greatly on the experience and background of the scientists who are conducting the studies. Although this benchmarking survey shows significantly diversified approaches among the participating companies, the diversity is not as great as one might expect based on the lack of clear guidance in literature or in regulatory guidelines. For example, it appears that most companies attempt to induce 2% degradation while limiting how harshly they will stress drugs (e.g., maximum temperatures, maximum and minimum ph conditions, and maximum length of time). On the other hand, the temperatures, ph conditions, and the duration of studies appear to vary considerably. Most companies are using high-performance LC with UV detection as the primary analytical methodology for stress testing studies. Fourteen companies indicate that they attempt to identify the major degradation product that occurs during stress testing, and three companies indicate that they only identify those stress testing degradation products that also are formed during formal stability studies at levels approaching or exceeding the impurity threshold limits. The authors hope that this survey will provide useful information to the pharmaceutical industry about conducting stress testing studies. It seems likely, however, that this survey will raise additional questions for the interested pharmaceutical researcher. The authors of this article recognize this potential and have proposed a follow-up conference specifically focused on stress testing. Acknowledgments Melissa Bolanos (KMR), Todd Hatajik (Pfizer), Patrick J. Jansen (Eli Lilly), W. Kimmer Smith (Eli Lilly), and Kimberly Snyder (Pfizer) for their assistance in developing and reviewing the stress testing survey. Reference 1. D.W. Reynolds et al., Available Guidance and Best Practices for Conducting Forced Degradation Studies, Pharm. Technol. 26 (2), 48 4 (22). 2. Guideline, Stability Testing: Photostability Testing of New Drug Substances and Products, November PT FYI Improved site security Members of the Synthetic Organic Chemical Manufacturers Association (SOCMA) formally adopted the Security Code of Management Practices as part of SOCMA s Responsible Care program. Implementation of the new security code is now a condition of membership. To help member firms implement the new security practices, SOCMA developed an on-line chemical-site Security Vulnerability Analysis methodology and a computer-based model to help enhance existing security efforts at batch and specialty chemical manufacturing facilities.the tools can be downloaded by members and nonmembers at no charge from SOCMA s Web site, 72 Pharmaceutical Technology FEBRUARY 2
STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW
More informationPHOTOSTABILITY TESTING OF NEW ACTIVE SUBSTANCES AND MEDICINAL PRODUCTS *)
PHOTOSTABILITY TESTING OF NEW ACTIVE SUBSTANCES AND MEDICINAL PRODUCTS *) Guideline Title Photostability Testing of New Active Substances and Medicinal Products *) Legislative basis Directive 75/318/EEC
More informationInternational Journal of Generic Drugs
Photostability STABILITY TESTING in New Drug Products evaluating photostability is foremost for new chemical entities only - not in generic drugs, provided the container-closure protection is the same
More informationInternational Journal of Research in Pharmacology & Pharmacotherapeutics
International Journal of Research in Pharmacology & Pharmacotherapeutics ISSN Print: 2278-2648 IJRPP Vol.5 Issue 4 Oct - Dec - 2016 ISSN Online: 2278-2656 Journal Home page: Review article Open Access
More informationImpurities from degradation of Drug Substances
Impurities from degradation of Drug Substances REFERENCE 1. ICH - IMPURITIES IN NEW DRUG SUBSTANCES - Q3A(R2) 2. ICH - IMPURITIES IN NEW DRUG PRODUCTS - Q3B(R2) 3. ICH - VALIDATION OF ANALYTICAL PROCEDURES:
More informationSTABILITY TESTING OF NEW DRUG
VICH GL5 (STABILITY 3) May 1999 For implementation at Step 7 STABILITY TESTING ESTING: PHOTOSTABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS Recommended for Implementation at
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationThe GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G
The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G (1) INTRODUCTION The following guideline defines the stability data package for a drug
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More informationSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
More informationINTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
International Journal of Institutional Pharmacy and Life Sciences 5(3): May-June 2015 INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES Pharmaceutical Sciences Review Article!!! Received:
More informationFOOD AND DRUGS AUTHORITY
G H A N A FOOD AND DRUGS AUTHORITY GUIDELINES FOR STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS AND FINISHED PHARMACEUTICAL PRODUCTS Document No: FDA/DRI/DER/GL-STP/2013/07 Date of First Adoption:
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 17 December 2003 CPMP/QWP/122/02, rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE
More informationSTABILITY: STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES (REVISION)
VICH GL3(R) (QUALITY) January 2007 Revision at Step 9 For Implementation at Step 7 STABILITY: STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES (REVISION) Recommended for Adoption at Step 7 of the VICH
More informationVICH Topic GL3. Step 7 (after revision at step 9) GUIDELINE ON STABILITY: STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 19 February 2007 Doc. Ref.EMEA/CVMP/VICH/899/99-Rev.1 VICH Topic GL3 Step 7 (after revision at step 9) GUIDELINE ON STABILITY: STABILITY
More informationNOTICE Our file number:
September 25, 2003 NOTICE Our file number: 03-118437-914 Adoption of ICH 1 Guidance: - This guidance document is a revised version of the ICH Q1A(R) guidance document and defines the stability data package
More informationGUIDELINE FOR THE STABILITY TESTING
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 GUIDELINE FOR THE STABILITY TESTING OF NON-PRESCRIPTION (OTC)
More informationAnalytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
More informationFDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability
More informationWorkshop Summaries. Discussions of the Global Stability Workshop are summarized for the following topics:
Workshop Summaries Discussions of the Global Stability Workshop are summarized for the following topics: QbD and Stability Program Dr. Alasandro Setting Specifications Dr. Gentry Challenges of Different
More informationChapter -1. Importance of Stability Indicating Analytical Methods for Analyzing Organic Impurities in Active Pharmaceutical Ingredients
Chapter -1 Importance of Stability Indicating Analytical Methods for Analyzing Organic Impurities in Active Pharmaceutical Ingredients 1.1 Introduction and importance of stability indicating analytical
More informationDraft regional guidelines on stability testing of active substances and pharmaceutical products
Regional Committee for the EM/RC53/12 Eastern Mediterranean August 2006 Fifty-third Session Original: Arabic Agenda item 17 Draft regional guidelines on stability testing of active substances and pharmaceutical
More informationAnnex 10. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. Introduction and background
Annex 10 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products Introduction and background The guidance on Stability testing of active pharmaceutical ingredients and
More informationPharmaceutical Sciences
SRI International Biosciences From Idea to IND Research on Disease Mechanisms Drug Discovery Drug Metabolism, Pharmacokinetics, & Toxicology Services Pharmaceutical Sciences Preclinical Development Planning
More informationGuidance for Industry
Guidance for Industry ANDAs: Impurities in Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationGuidance for Industry Q3B(R2) Impurities in New Drug Products
Guidance for Industry Q3B(R2) Impurities in New Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationStability Report. Accelerated and long-term testing. with registration batches. BIWG 98 SE drug substance SR
Stability Report Accelerated and long-term testing with registration batches BIWG 98 SE drug substance Number SR 200-02-01 Date Page 00.00. 0000 1 of 30 Responsible Company Successful Pharma KG Biberach
More informationChapter 2 deals with LC-ESI-MS/MS studies on forced degradation of abacavir sulphate an anti HIV drug.
The drug discovery and development process has undergone dramatic changes particularly in the last decade. Progress in drug discovery has been fuelled by improvements in methodologies and technologies
More informationCMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.
CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationGUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA
GUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA Issued by the Registrar: Act No. 36 of 1947, Private Bag X343, Pretoria 0001 Republic of South Africa Tel. (**27
More informationDEPARTMENT OF AGRICULTURE, FORESTRY & FISHERIES STABILITY
DEPARTMENT OF AGRICULTURE, FORESTRY & FISHERIES STABILITY This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of Stock Remedies. It represents
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationBehavior of Uptake of Moisture by Drugs and Excipients under
Behavior of Uptake of Moisture by Drugs and Excipients under Accelerated Conditions of Temperature and Humidity in the Absence and the Presence of Light Part II: Packaged and Unpackaged Antituberculosis
More informationGuidelines for Pharmaceutical Equivalence Requirements
Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 1 September 2010 Page 1 of 9 Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 Drug Sector Saudi Food & Drug Authority
More informationGUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET
GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda
More informationAnalytical and formulation attributes
Peer reviewed article Analytical and formulation attributes in developing generic sterile injectable liquid and lyophilized drugs (part 1) Arindam Roy ARINDAM ROY 1,2 *, GURMUKH CHANANA 1 *Corresponding
More information9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization
USP Monograph Modernization Procedure Review and Development Donald Min 2 USP basic Since USP's founding in 1820, our operations have grown exponentially: from 11 volunteers collaborating from their respective
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group
ASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group Version Description of Change Author Effective Date v 1.0 Original publication ASMF/DMF WG May 26, 2015 v 1.1 Watermark added ASMF/DMF
More informationInternational Pharmaceutical Excipients Council Of The Americas
October 6, 2008 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Subject: FDA Draft Guidance for Industry, Residual Solvents in Drug
More informationANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS
Association of South East Asian Nations (ASEAN) ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS Disclaimer: This document is provided for information purpose only and subject
More informationICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/142/95 ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE
More informationA STANDARD PROTOCOL for DERIVING and ASSESSMENT of STABILITY. Part 3 Oral Liquid Medicines (Solutions, Emulsions, Suspensions and Syrups)
A STANDARD PROTOCOL for DERIVING and ASSESSMENT of STABILITY Part 3 Oral Liquid Medicines (Solutions, Emulsions, Suspensions and Syrups) EDITION 1 August 2014 NHS Pharmaceutical Quality Assurance Committee
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationYour bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationQbD in developing semisolid formulations
QbD in developing semisolid formulations 4th Jerusalem Conference on Quality and Pharma Sciences Haim Barsimantov, COO, Sol-Gel 21.05.13 Outline Drug Product Specification - definition In Process Control
More informationá1225ñ VALIDATION OF COMPENDIAL PROCEDURES
1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst
More informationCurrent Trends in Performance of Forced Degradation Studies and Stability Indicating Studies of Drugs
IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-issn:2278-3008, p-issn:2319-7676. Volume 12, Issue 6 Ver. II (Nov. Dec. 2017), PP 17-36 www.iosrjournals.org Current Trends in Performance
More informationForced Degradation of Ibuprofen in Bulk Drug and Tablets
Forced Degradation of Ibuprofen in Bulk Drug and Tablets and Deteration of Specificity, Selectivity, and the Stability-Indicating Nature of the USP Ibuprofen Assay Method Sherri Farmer, Pamela Anderson,
More informationVICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES
European Medicines Agency Veterinary Medicines and Inspections London, 19 February 2007 Doc. Ref.EMEA/CVMP/VICH/837/99-Rev.1 VICH Topic GL10 Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN
More informationExpert decision support software for predicting the forced degradation pathways of organic compounds
Expert decision support software for predicting the forced degradation pathways of organic compounds Index P3 Introduction to Zeneth Zeneth is an expert, knowledge-based software that gives accurate forced
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationHarmonizing Standards and Specifications
WASHINGTON REPORT Harmonizing Standards and Specifications Jill Wechsler Manufacturers seek more FDA guidance about establishing product specifications during drug development as part of the agency s efforts
More informationPublic Assessment Report Scientific discussion. Olanzapine Accord (olanzapine) SE/H/866/01-06/DC
Public Assessment Report Scientific discussion Olanzapine Accord (olanzapine) SE/H/866/01-06/DC This module reflects the scientific discussion for the approval of Olanzapine Accord. The procedure was finalised
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationAn Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications
An Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications On behalf of Specifications Team Kirby Wong-Moon, Ph.D. Amgen Inc. Best Practices and Application of GMPs for
More informationElemental impurities impact on APIs
Regulatory Expectations on impurities in Drug Substances: Authority and Industry perspective Pavia, 2nd October 2015 Elemental impurities impact on APIs October 2 nd 2015 Annalisa Scali RegulatoryAffairsManager
More informationPublic Assessment Report Scientific discussion. Olanzapine Accord (olanzapine) SE/H/866/01-06/DC
Public Assessment Report Scientific discussion Olanzapine Accord (olanzapine) SE/H/866/01-06/DC This module reflects the scientific discussion for the approval of Olanzapine Accord. The procedure was finalised
More informationAntibody-Drug Conjugates The Road to the Current State. Nila Das, Ph.D. American Drug Delivery & Formulation Summit San Diego, CA June 13, 2016
Antibody-Drug Conjugates The Road to the Current State Nila Das, Ph.D. American Drug Delivery & Formulation Summit San Diego, CA June 13, 2016 1 Current Status of ADCs C&E News. 2014, 92(3): 13-21 2 Current
More informationTechnical requirements to Good Manufacturing Practice in metered dose inhalers production and development (2. part) Extractable - Leachable
Technical requirements to Good Manufacturing Practice in metered dose inhalers production and development (2. part) Extractable - Leachable Dr. Gyula Körtvélyessy UNIDO Honorary Secretary General of the
More informationPerspectives on Method Validation: Importance of Adequate Method Validation
Perspectives on Method Validation: Importance of Adequate Method Validation Heather Bridwell, Vikas Dhingra, Daniel Peckman, Jennifer Roark and Thomas Lehman The appropriate validation of analytical methods
More informationCHAPTERS 1, 2 and 3 CHAPTER-4 CHAPTER-5,
319 Presently in the pharmaceutical industry, drug analysis plays a vital role in deciding the quality and potency of the drug. The selection of analytical method used to quantify the drugs and impurities
More informationReference Standards for Monoclonal Antibodies: Key Challenges Addressed
CASSS WCBP 2012: 16th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products January 23-25, 2012 Reference Standards for Monoclonal Antibodies: Key Challenges
More information3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry. Global Expertise delivered locally
3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry Global Expertise delivered locally Global expertise delivered locally As a global leader in measuring,
More informationManual 055 Commercial Stability Testing For Formulated Products. This procedure applies to all drug products. The procedure covers:
1 Purpose Manual 055 Commercial Stability Testing For Formulated Products The intent of this procedure is to provide to manufacturing and primary packaging sites the principles of a stability program.
More informationPharmacopoeial Reference Standards
Pharmacopoeial Reference Standards Industry view point Antony Raj Gomes Head- Quality Management 1 Presentation Overview Indian Industry an update Available guidelines Industry practices Current challenges
More informationASCENDIA PHARMACEUTICALS Aspiring for Better Medicine
ASCENDIA PHARMACEUTICALS Aspiring for Better Medicine Ascendia Pharmaceuticals, founded in 2012, is a privately-owned, speciality pharmaceutical company dedicated to developing enhanced formulations of
More informationCharacterization of mab aggregation using a Cary 60 UV-Vis Spectrophotometer and the Agilent 1260 Infinity LC system
Characterization of mab aggregation using a Cary 60 UV-Vis Spectrophotometer and the Agilent 1260 Infinity LC system Application Note Biopharmaceuticals Authors Arunkumar Padmanaban and Sreelakshmy Menon
More informationApplication Note. Authors. Abstract. Biopharmaceuticals
Characterization of monoclonal antibodies on the Agilent 126 Infinity Bio-inert Quaternary LC by Size Exclusion Chromatography using the Agilent BioSEC columns Application Note Biopharmaceuticals Authors
More information1.1. Overview of Drug Stability Studies
1.1. Overview of Drug Stability Studies Everything made by human hands is known to deteriorate and pharmaceutical product is no exception to it. Degradation is a phenomenon where certain measurements of
More informationFuture of Question-based Review and Regulatory Submissions
Future of Question-based Review and Regulatory Submissions Robert Iser Associate Director for Policy Development (Acting) Office of Pharmaceutical Science / CDER / FDA FDA/PQRI Conference on Evolving Product
More informationCorso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche E25. Fabbricazione Industriale dei Medicinali 4 CFU Prof.
Sezione di Tecnologia e Legislazione Farmaceutiche Maria Edvige Sangalli Corso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche E25 Fabbricazione Industriale dei Medicinali 4 CFU Prof. Andrea
More informationAutomating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper
Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper Varian, Inc. 2700 Mitchell Drive Walnut Creek, California 94598, USA www.varianinc.com Introduction Chromatographic
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationStability testing is required for
FOCUS ON... ANALYTICS Outsourcing Stability Testing Discussions with Contract Laboratories by Maribel Rios Stability testing is required for all biopharmaceutical drug products to detect all changes in
More informationNew Drug Product Impurities
Title Page Image - with courtesy of the FDA CDER original web site at www. cder.fda.gov/ New Drug Product Impurities IAGIM Scientific Committee Block JD; Holmann E ; West P NEW DRAFT GUIDANCE FDA Viewpoint
More informationCase study 2: Parenteral Drug Product
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Purpose of Case Study 2: The following case study provides one example of a summary of an elemental impurities risk
More informationFormulation Development & CTM Manufacturing Services
Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range
More informationMass Detection for the Chromatographer Waters ACQUITY QDa Detector
Mass Detection for the Chromatographer Waters ACQUITY QDa Detector Warren B Potts III Senior Director Americas Marketing warren_potts@waters.com 2017 Waters Corporation 1 Agenda Overview of technology
More informationAutomating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper
Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper S-Matrix Corporation 1594 Myrtle Avenue Eureka, CA 95501, USA www.smatrix.com Introduction Chromatographic analytical
More informationM7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk This draft guidance, when finalized, will represent the Food and Drug Administration's
More informationEffective Management and Operations of GXP Laboratories
Effective Management and Operations of GXP Laboratories Course Objective: Upon completion of this course, attendees involved in establishing and assuring that Good Laboratory / Good Manufacturing Practice
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
More informationDevelopment of stability indicating studies for pharmaceutical products: an innovative step
Review Article Development of stability indicating studies for pharmaceutical products: an innovative step Gunjan Rao 1, Anju Goyal 2,* Bhopal Nobel s Institute of Pharmaceutical Sciences, Udaipur, Rajasthan
More informationCOMMERCIAL PRODUCT STABILITY
COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality
More informationRepeatability of C100ht Biologics Analyzer, for High Throughput Glycan Screening
Repeatability of C100ht Biologics Analyzer, for High Throughput Glycan Screening Marcia Santos, Tingting Li, Mervin Gutierrez, Anna Lou, and Clarence Lew SCIEX Separations, Brea, CA Introduction The ability
More informationQuestion-based Review (QbR)
Question-based Review (QbR) Rebecca L. Owen, Ph.D. Team Leader, Feed/Topical Team Division of Manufacturing Technologies ONADE/CVM/FDA Outline Background on CMC Filing Requirements What is QbR? QbR at
More informationCHANGE CONTROL MANAGEMENT FOR A STABILITY PROGRAM
Potential Changes and Minimizing the Impact of Registration CHANGE CONTROL MANAGEMENT FOR A STABILITY PROGRAM Kim Huynh Ba Eecutive Director PHARMALYTIK www.pharmalytik.com Biography Kim Huynh Ba has over
More informationAnalysis of Protein Biopharmaceuticals
Analysis of Protein Biopharmaceuticals Comprehensive cgmp Services at Every Stage of Drug Development Amazing where you can go At Solvias, we work closely with you Solvias provides comprehensive services
More informationIntegrated Formulation, Testing and Analysis Program for Trans Sodium Crocetinate (TSC)
Integrated Formulation, Testing and Analysis Program for Trans Sodium Crocetinate (TSC) ONR Contract No: N00014-05-C-0257 Quarterly Report February 1, 2006 - April 30, 2006 David G. Kalergis, Principal
More informationPharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148
Request for Proposal Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Dated: October 12 th 2015 Page 1 Table of Contents 1. PURPOSE... 3 2. RFP
More informationICH 교육가이드라인 [ 안전성 & 품질 ]
ICH 교육가이드라인 [ 안전성 & 품질 ] 1 SAFETY ( 안전성 ) Safety Series / 11 월 27 일 ( 화 ) ICH S9 guideline is focused on anticancer drugs. However, for better understanding, the presentation will give the comparison with
More informationINTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
International Journal of Institutional Pharmacy and Life Sciences 5(1): January-February 2015 INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES Pharmaceutical Sciences Review Article!!!
More informationMASTER FILE PROCEDURES
MASTER FILE PROCEDURES Natural Health Products Directorate August 2006 Version 1.0 Our mission is to help the people of Canada maintain and improve their health, while respecting individual choices and
More informationPresentazione: Use of coupled chromatographic analytical. registration of new medicinal products. Relatore: Dr.ssa Federica Bruno
Presentazione: Use of coupled chromatographic analytical techniques (HPLC/MS; GC/MS) in the registration of new medicinal products Relatore: Dr.ssa Federica Bruno date: 21 Ottobre 2016 Public Declaration
More informationLonza Nansha, China For Global Excellence in Advanced Chemical Synthesis
Pharma&Biotech Lonza Nansha, China For Global Excellence in Advanced Chemical Synthesis Lonza Guangzhou Nansha Ltd «Twenty-five years ago Lonza built one of the world s most advanced cgmp chemical manufacturing
More information